Trial · NCT06784349
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment Emergent Adverse Events (TEAEs) | Through Week 44 | |
| Primary | Severity of TEAEs | Through Week 44 | |
| Primary | Percent changes in fasting concentrations of High-Density Lipoprotein Cholesterol (HDL-C) | Baseline to week 24 | Part B Only |
| Secondary | Concentration of combined ALN-APOC3 and metabolites in plasma | Through Week 44 | |
| Secondary | Urinary excretion of combined ALN-APOC3 and metabolites | Through 24 Hours, After Treatment | Part A Only |
| Secondary | Percent change in fasting concentrations of APOC3 | Baseline to Week 12 | |
| Secondary | Absolute change in fasting concentrations of APOC3 | Baseline to Week 12 | |
| Secondary | Percent change in fasting concentrations of APOC3 | Baseline to Week 24 | Part B Only |
| Secondary | Absolute change in fasting concentrations of APOC3 | Baseline to Week 24 | Part B Only |
| Secondary | Percent change in fasting concentrations of HDL-C | Baseline to Week 12 | |
| Secondary | Absolute change in fasting concentrations of HDL-C | Baseline to Week 12 | |
| Secondary | Absolute change in fasting concentrations of HDL-C | Baseline to Week 24 | Part B Only |
| Secondary | Percent change in fasting concentrations of Low-Density Lipoprotein Cholesterol (LDL-C) | Baseline to Week 12 | |
| Secondary | Absolute change in fasting concentrations of LDL-C | Baseline to Week 12 | |
| Secondary | Percent change in fasting concentrations of LDL-C | Baseline to Week 24 | Part B Only |
| Secondary | Absolute change in fasting concentrations of LDL-C | Baseline to Week 24 | Part B Only |
| Secondary | Percent change in fasting concentrations of Triglycerides (TG) | Baseline to Week 12 | |
| Secondary | Absolute change in fasting concentrations of TG | Baseline to Week 12 | |
| Secondary | Percent change in fasting concentrations of TG | Baseline to Week 24 | Part B Only |
| Secondary | Absolute change in fasting concentrations of TG | Baseline to Week 24 | Part B Only |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06784349/registered